By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Cell Signaling Technology today announced it has licensed its patent rights and proprietary antibody reagents related to the detection of epidermal growth factor receptor mutations to Ventana Medical Systems.

The non-exclusive licensing agreement is for the field of tissue-based in vitro diagnostics testing, the Danvers, Mass.-based antibody firm said. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.